Healthcare is well positioned to be the megatrend of the 2020s because of demographic tailwinds, rising healthcare spending, sound earnings, and breakthrough innovation. That offers a wide range of investment opportunities, Mark Denham writes in his essay for finews.first.


finews.first is a forum for authors to comment on economic and financial topics.


As the population ages, chronic diseases grow in prevalence, and medicine advances, healthcare companies are situated at the heart of a number of major structural changes impacting society. Against this backdrop, the sector provides an attractive pool of long-term investments, with many companies delivering solid earnings and high-profit margins.

With artificial intelligence (AI) set to provide support for doctors and researchers to make more data-driven decisions, the sector’s growth prospects remain compelling.

«Biotech companies tend to offer a high-growth profile, but most of them are small and early stage»

The healthcare sector is made up of many different industries – from pharmaceuticals and devices to health insurers and hospitals – and each has different dynamics. Not only do these various subsectors offer a wide range of investment opportunities they can also act as an interesting portfolio construction tool, especially during economic downturns.

People continue to require medical care regardless of the economic climate, which can make healthcare investments less susceptible to market volatility compared to other industries. In addition, healthcare naturally contributes to improving living standards which meet the growing demand from investors for socially responsible stocks.

Beyond the well-known pharmaceuticals segment – which accounts for 40 percent of the MSCI Healthcare sector – and is generally seen as defensive by investors, there is the biotech segment that has a very different profile. Biotech companies tend to offer a high-growth profile, but most of them are small and early stage meaning that they could be loss operating for years, and even more risks due to the potential that some products under development may never make it to market. In the coming months, the segment should benefit from both resilient growth in the US and rate cuts that could revive sector interest and M&A activity.

«One theme dominating the healthcare discourse is obesity treatment»

Other subsectors offer a steady and secular growth profile, at attractive valuations such as life science tools. The sector has suffered from consumable inventory destocking after many end-customers overordered during the pandemic. We are getting to the end of this process and concerns are priced in. Therefore, the question is not about whether there will be a recovery, but rather when the recovery will occur.

One theme dominating the healthcare discourse is obesity treatment. With over one in eight adults worldwide being overweight and almost half of Americans projected to be obese by 2030, healthcare spending on related conditions is expected to increase.

The market for GLP1 drugs that have proven highly effective in treating obesity is estimated to reach $100bn in peak sales by the early 2030s. The market share should be split relatively equally between Novo Nordisk and Eli Lilly, the two main companies behind these drugs. Wegovy (Novo Nordisk) or Zepbound (Eli Lilly) would result in a net saving (hospital costs, etc.) of around 7,000 British pounds ($8,760) per patient, according to a recent report by the UK NHS.

«Healthcare can represent a genuine source of alpha for investors»

However, the challenge is to convince insurers and governments across the world to cover the cost of these drugs, which are often out of reach for most people. To address this, weight loss drugs need to offer additional health benefits. For instance, during late-stage trial preliminary results, Novo Nordisk's Wegovy drug was able to show a 20 percent reduction in cardiovascular events, i.e. heart attacks/strokes, for people treated with weight loss drugs vs. placebo.

Despite the past two years of strong performance in the obesity theme, we believe that the two leaders will continue to thrive. Analysts' forecasts have not fully accounted for the ongoing momentum in diabetes prescriptions and the significant increase in the supply of drugs for obesity, which met the growing demand in 2024 and beyond.

With both long-term structural changes and short-term innovation providing powerful tailwinds for the sector it is clear healthcare can represent a genuine source of alpha for investors. And, with the sector’s breadth, idiosyncrasies, and multiple performance drivers, it provides fertile ground for stock pickers from both fundamental and portfolio diversification perspectives.


Mark Denham is the Head of Equities and the Manager of the Carmignac Portfolio Grandchildren.


Previous contributions: Rudi BogniPeter KurerRolf BanzDieter RuloffWerner VogtWalter WittmannAlfred MettlerRobert HolzachCraig MurrayDavid ZollingerArthur BolligerBeat KappelerChris RoweStefan GerlachMarc LussyNuno Fernandes, Richard EggerMaurice PedergnanaMarco BargelSteve HankeUrs Schoettli, Ursula FinsterwaldStefan Kreuzkamp, Oliver BussmannMichael Benz, Albert SteckMartin Dahinden, Thomas FedierAlfred MettlerBrigitte StrebelMirjam Staub-BisangNicolas RothThorsten PolleitKim IskyanStephen DoverDenise Kenyon-RouvinezChristian DreyerKinan Khadam-Al-JameRobert HemmiAnton AffentrangerYves Mirabaud, Katharina BartFrédéric PappHans-Martin KrausGerard GuerdatMario BassiStephen ThariyanDan SteinbockRino BoriniBert FlossbachMichael HasenstabGuido SchillingWerner E. RutschDorte Bech Vizard, Katharina BartMaya BhandariJean TiroleHans Jakob RothMarco MartinelliThomas SutterTom KingWerner PeyerThomas KupferPeter KurerArturo BrisFrederic PappJames SymeDennis Larsen, Bernd Kramer, Armin JansNicolas RothHans Ulrich JostPatrick HungerFabrizio QuirighettiClaire ShawPeter FanconiAlex Wolf, Dan Steinbock, Patrick ScheurleSandro OcchilupoWill BallardNicholas YeoClaude-Alain Margelisch, Jean-François HirschelJens Pongratz, Samuel GerberPhilipp WeckherlinAnne RichardsAntoni TrenchevBenoit BarbereauPascal R. BersierShaul LifshitzKlaus BreinerAna BotínMartin GilbertJesper KollIngo RauserCarlo CapaulMarkus WinklerThomas SteinemannChristina BoeckGuillaume CompeyronMiro Zivkovic, Alexander F. WagnerEric HeymannChristoph SaxFelix BremJochen MoebertJacques-Aurélien MarcireauUrsula FinsterwaldMichel Longhini, Stefan BlumZsolt KohalmiNicolas RameletSøren BjønnessGilles PrinceSalman AhmedPeter van der WelleKen OrchardChristian GastJeffrey Bohn, Juergen BraunsteinJeff VoegeliFiona Frick, Stefan Schneider, Matthias HunnAndreas Vetsch, Fabiana Fedeli,  Kim FournaisCarole MilletSwetha RamachandranThomas StuckiNeil ShearingTom Naratil, Oliver Berger, Robert SharpsTobias MuellerFlorian WickiJean KellerNiels Lan DokyJohnny El HachemJudith BasadKatharina BartThorsten PolleitPeter SchmidKaram HindujaZsolt Kohalmi, Raphaël SurberSantosh Brivio, Mark UrquhartOlivier Kessler, Bruno CaponePeter HodyMichael BornhaeusserAgnieszka Walorska, Thomas MuellerEbrahim Attarzadeh, Marcel HostettlerHui ZhangMichael BornhaeusserReto JauchAngela AgostiniGuy de BlonayTatjana Greil CastroJean-Baptiste BerthonMarc Saint John WebbDietrich GoenemeyerMobeen TahirDidier Saint-GeorgesSerge TabachnikVega IbanezDavid Folkerts-LandauAndreas ItaMichael Welti, Fabrizio PaganiRoman BalzanTodd SaligmanChristian KaelinStuart DunbarCarina SchaurteBirte Orth-FreeseGun WooLamara von AlbertiniRamon VogtAndrea HoffmannNiccolò GarzelliDarren WilliamsBenjamin BöhnerMike JudithJared CookHenk GrootveldRoman GausNicolas FallerAnna StünziThomas Höhne-SparborthFabrizio PaganiGuy de BlonayJan BoudewijnsSean HagertyAlina DonetsSébastien GalyRoman von AhFernando FernándezGeorg von WyssStefan BannwartAndreas BrittFrédéric LerouxNick PlatjouwRolando GrandiPhilipp KaupkeGérard PiaskoBrad SlingerlendDieter WermuthGrégoire BordierThomas Signer, Gianluca GerosaChristine HoustonManuel Romera RoblesFabian KäslinClaudia KraazMarco HuwilerLukas ZihlmannSherif MamdouhHarald PreisslerTaimur HyatPhilipp CottierAndreas HerrmannCamille VialMarcus Hüttinger, Serge BeckAlannah BeerStéphane MonierAshley SimmonsLars JaegerShanna Strauss-FrankBertrand Binggeli, Marionna WegensteinGeorge Muzinich, Jian Shi CortesiRazan NasserNicolas ForestJoerg RuetschiReto JauchBernardo BrunschwilerCharles-Henry MonchauPhilip Adler, Ha DuongTeodoro CoccaBeat WittmannJan BrzezekFlorin BaeriswylNicolas Mousset, Beat WeissPascal MischlerAndrew IsbesterKonrad HummlerJan BeckersMartin VeltenKatharine NeissClaude BaumannDaniel RoartyKubilay YalcinRobert AlmeidaKarin M. KlossekMarc TavernerCharlie T. MungerDaniel KoblerPatrick StauberColin Vidal, Anna Rosenber, Judith Wallenstein, Adriano Lucatelli, Daniel Goleman, Val Olson, Brice Prunas, Francesco Magistra, Brigitte Kaps, Frances Weir, Luis Maldonado, Francesco Mandalà, Francesco Magistra, Nadège Lesueur-Pène, Massimo Pedrazzini, Eric Sarasin, David Ellis, Dina Ting, Christopher Gannatti, Shaniel Ramjee, Mihkel Vitsur, Nannette Hechler-Fayd’herbe, Ralph Ebert, and Chris Cottorone.